GlassScriptPhysician profile
Marina Kovalevsky
NPI 1144377607
$16,464.04
in general payments reported to CMS, 2019-2025
54 companies · $1,958 in 2025
The $1,958 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,128 · 2020: $2,391 · 2021: $2,981 · 2022: $2,255 · 2023: $2,623 · 2024: $2,128 · 2025: $1,958.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,708.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,708.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,579.21 | 2019-2025 | |
| Amgen INC. | $2,243.55 | 2019-2025 | Evenity, Prolia, Repatha |
| Astrazeneca Pharmaceuticals LP | $1,490.62 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $946.02 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $785.22 | 2020-2025 | |
| Amarin Pharma, INC. | $755.05 | 2019-2023 | |
| Novo Nordisk INC | $712.84 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $530.42 | 2019-2025 | Xifaxan, Trulance |
| Sanofi-Aventis U.S. LLC | $524.85 | 2019-2023 | |
| Pfizer INC. | $472.91 | 2019-2024 | |
| Almatica Pharma LLC | $457.35 | 2021-2025 | Loreev Xr, Teriparatide, Gralise |
| Astellas Pharma US INC | $429.31 | 2019-2021 | |
| Lilly USA, LLC | $372.88 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $332.89 | 2019-2025 | Synjardy, Jardiance, Tradjenta |
| Sumitomo Pharma America, INC. | $309.75 | 2023-2025 | Gemtesa |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marina Kovalevsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.